Original InvestigationCoronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This trial was funded by The Chief Scientist Office of the Scottish Government Health and Social Care Directorates (CZH/4/588), with supplementary awards from the British Heart Foundation (RE/13/3/30183), Edinburgh and Lothian’s Health Foundation Trust and the Heart Diseases Research Fund. The Royal Bank of Scotland supported the provision of 320-multidetector CT for NHS Lothian and the University of Edinburgh. The Edinburgh Imaging facility QMRI (Edinburgh) is supported by the National Health Service Research Scotland (NRS) through National Health Service Lothian Health Board. The Clinical Research Facility Glasgow and Clinical Research Facility Tayside are supported by the NRS. Drs. Williams (FS/11/014) and Newby (CH/09/002, RE/13/3/30183) are supported by the British Heart Foundation. Dr. Williams (FS/11/014) is supported by The Chief Scientist Office of the Scottish Government Health (PCL/17/04). Drs. Williams and Nicol have served as consultants for GE Healthcare. Dr. Dweck is supported by the British Heart Foundation (FS/14/78/31020) and the Sir Jules Thorn Biomedical Research Award 2015 (15/JTA). Dr. Roditi has received honoraria from Bracco, Bayer-Schering, GE Healthcare, and Guerbet, which produce contrast media. Drs. Roditi, van Beek, and Newby have received honoraria and consultancy from Toshiba Medical Systems. Dr. van Beek is supported by the Scottish Imaging Network: A Platform of Scientific Excellence. Dr. Newby has received a Wellcome Trust Senior Investigator Award (WT103782AIA). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.